U.S. markets open in 1 hour 21 minutes

Autolus Therapeutics plc (AUTL)

NasdaqGS - NasdaqGS Real Time Price. Currency in USD
Add to watchlist
15.44+0.07 (+0.46%)
At close: 4:00PM EDT
Full screen
Trade prices are not sourced from all markets
Gain actionable insight from technical analysis on financial instruments, to help optimize your trading strategies
Chart Events
Bullishpattern detected
Triple Moving Average Crossover

Triple Moving Average Crossover

Previous Close15.37
Open15.51
Bid0.00 x 1100
Ask0.00 x 1100
Day's Range15.02 - 15.66
52 Week Range3.00 - 17.19
Volume147,689
Avg. Volume221,498
Market Cap806.746M
Beta (5Y Monthly)1.96
PE Ratio (TTM)N/A
EPS (TTM)-1.40
Earnings DateMay 07, 2020
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target Est28.38
Fair Value is the appropriate price for the shares of a company, based on its earnings and growth rate also interpreted as when P/E Ratio = Growth Rate. Estimated return represents the projected annual return you might expect after purchasing shares in the company and holding them over the default time horizon of 5 years, based on the EPS growth rate that we have projected.
Fair Value
XX.XX
Overvalued
Research that delivers an independent perspective, consistent methodology and actionable insight
Related Research
View more
  • GlobeNewswire

    Autolus Therapeutics Reports Second Quarter 2020 Financial Results and Operational Progress

    \- Conference call to be held on August 6, 2020 at 8:30 am EDT/1:30 pm BST -LONDON, Aug. 06, 2020 (GLOBE NEWSWIRE) -- Autolus Therapeutics plc (Nasdaq: AUTL), a clinical-stage biopharmaceutical company developing next-generation programmed T cell therapies, today announced its financial and operational results for the second quarter ended June 30, 2020. “We have had a busy second quarter with data updates across our portfolio at key medical and scientific conferences,” said Dr Christian Itin, chairman and chief executive officer of Autolus.   “Both our later stage programs, AUTO1 and AUTO3, continue to show encouraging clinical activity with tolerable safety in adult patients with ALL and DLBCL, respectively, and we are excited by the potential for these product candidates to have differentiated profiles addressing indications with high unmet needs.  We look forward to providing further updates in H2 2020, starting with AUTO3 ALEXANDER data at a mini oral session at ESMO in September.”“At AACR we presented data across a number of next generation programs,” said Dr Martin Pule, chief scientific officer of Autolus. “These data demonstrate the strength of our binder discovery capabilities with highly selective targeting in AUTO5 for T Cell lymphoma, as well as the ability of our cell programming modules to address the hostile solid tumor microenvironment as shown for AUTO6NG and AUTO7 for small cell lung cancer and prostate cancer, respectively. We are excited to be progressing these next generation programs into Phase 1 in 2021.”Pipeline Updates: * AUTO1 in acute lymphocytic leukemia (ALL). Positive data were presented at the European Hematology Association (EHA) meeting in June 2020.  These data showed an encouraging durability of response without subsequent stem cell transplant and confirmed the safety profile.  Autolus has now started enrolment of adult patients with relapsed / refractory ALL in its pivotal Phase 1b/2 AUTO1 program and is targeting to have full data by the end of 2021.    * AUTO3 in diffuse large B-cell lymphoma (DLBCL). Positive data were presented at the American Society of Clinical Oncology (ASCO) meeting in June 2020. These data showed a high level of complete remissions and a safety profile supportive of evaluation of outpatient use. Based on these data, Autolus selected its recommended Phase 2 dose range of 150 - 450 x 106 cells, with a single dose of pembrolizumab during preconditioning. In addition, the company has also commenced an outpatient cohort as an extension to its ongoing Phase 1/2 ALEXANDER study, with results expected in the second half of 2020. The data from this outpatient cohort will provide important insights that will be used to refine the design of the potential pivotal Phase 2 part of the ALEXANDER study. Autolus expects to present next updated data from the study at ESMO in September 2020.    * AUTO5 in T cell lymphoma. Positive preclinical data were presented at the American Association for Cancer Research II (AACR) Meeting in June 2020. The data highlight the specificity and selectivity of the company’s T-cell lymphoma product candidate, AUTO5.   * AUTO6NG in small cell lung cancer (SCLC). Positive preclinical data were presented at the AACR Meeting in June 2020. Autolus has designed enhancing modules to specifically overcome tumor microenvironment (TME) defenses in solid tumor settings. The new data suggest that AUTO6NG can overcome the immune suppressive mechanisms in the TME.   * AUTO7 in prostate cancer. Positive preclinical data were presented at an oral presentation at the AACR Meeting in June 2020. The program builds on a novel and optimized CAR to PSMA designed to be highly active, even in an acidic environment, and combines modules introduced in AUTO6NG with a novel low level secretion of IL-12 to change the prostate tumor from an immunologically cold to an immunologically supportive environment.Operational Highlights: * Appointment of Dr Jay T Backstrom to Autolus’ Board of Directors, effective August 1, 2020. Dr Backstrom currently serves as EVP, Head of Research & Development at Acceleron Pharma Inc. and prior to that served as CMO and Head of Regulatory Affairs at Celgene Corporation.   * Dr Nushmia Khokhar promoted to Senior Vice President, Clinical Development. Dr Khokhar will take over the clinical leadership role at Autolus. She is a board-certified oncologist with extensive early and late stage clinical development experience, having led several successful registration trials within the industry in both solid tumors and hematologic malignancies, including the global daratumumab program at Janssen Oncology. Dr Vijay Peddareddigari, Senior Vice President, Chief Medical Officer will be leaving the Company to return to the United States.   * Expanded manufacturing capacity at the Cell and Gene Therapy Catapult to secure initial commercial launch capability. Key Upcoming Clinical Milestones: * Further update for AUTO3 at ESMO in Q3 2020.   * Further data updates for both AUTO1 and AUTO3 in Q4 2020.   * First data from outpatient cohort in the AUTO3 ALEXANDER study in H2 2020.   * Interim Phase 1 data for AUTO4 in T cell lymphoma in H1 2021. * Initiation of Phase 1 study for AUTO1NG in pediatric ALL in H2 2020.   * Initiation of Phase 1 study for AUTO8 in multiple myeloma in H2 2020.   * Progression of additional next generation programs from preclinical stages to Phase 1 throughout 2021.    * Expansion of the company’s suite of cell programming technologies to include additional modules designed for allogeneic applications, with the first novel allogeneic program expected to enter the clinic in Q4 2020.Financial Results for the Quarter Ended June 30, 2020Cash and equivalents at June 30, 2020 totaled $212.0 million, compared with $243.3 million at March 31, 2020.Net total operating expenses for the three months ended June 30, 2020 were $39.5 million, net of grant income of $0.3 million, as compared to net operating expenses of $37.2 million, net of grant income of $0.3 million, for the same period in 2019.Research and development expenses increased to $31.3 million for the three months ended June 30, 2020 from $26.2 million for the three months ended June 30, 2019. Cash costs, which exclude depreciation and amortization as well as share-based compensation, increased to $26.5 million from $20.2 million. The increase in research and development cash costs of $6.3 million consisted primarily of (i) an increase in compensation and employment related costs, net of lower travel costs as a result of the ongoing pandemic, of $1.8 million due to an increase in employee headcount to support the advancement of our product candidates in clinical development, (ii) an increase of $3.0 million in project expenses as a consequence of the advancement of our clinical portfolio which includes research and process development and manufacturing activities necessary to prepare, activate, and monitor clinical trial programs, (iii) an increase of $1.3 million in facilities costs related to the commencement of a lease for an additional manufacturing suite and the continued scaling of operations in the manufacturing facility, and (iv) an increase in IT and telecoms, general office expense, and professional fees of $0.6 million, which is offset by a decrease in materials purchases of $0.4 million.  Non-cash costs decreased to $4.8 million for the three months ended June 30, 2020 from $6.0 million for the three months ended June 30, 2019. The decrease is primarily related to share-based compensation expense included in research and development expenses, which decreased by $1.3 million as a result of a lower fair value of stock options recognized in the period, offset by a small increase in depreciation.General and administrative expenses decreased to $8.5 million for the three months ended June 30, 2020 from $11.4 million for the three months ended June 30, 2019. Cash costs, which exclude depreciation expense as well as share-based expense compensation decreased to $6.7 million from $7.3 million. Compensation related expenses decreased by $0.1 million aided by lower travel costs as described above. Further there was a decrease of $0.7 million in commercial activities. These decreases were offset by an increase of $0.1 million in legal and professional fees. Non-cash costs decreased to $1.8 million for the three months ended June 30, 2020 from $3.9 million for the three months ended June 30, 2019. The decrease is attributed to share-based compensation expense as a result of the lower fair value of stock options recognized during the period.Interest income decreased by $1.1 million for three months ended June 30, 2020 due to lower interest rates.Other income decreased to $0.5 million for the three months ended June 30, 2020 from other income of $4.4 million for the three months ended June 30, 2019 primarily due to a decrease of the U.S. dollar exchange rate relative to the pound sterling during the three months ending June 30, 2020 as compared to the three months ended June 30, 2019.Income tax benefit increased to $7.0 million for the three months ended June 30, 2020 from $3.3 million for the three months ended June 30, 2019 due to increased R&D expenses, which led to a higher effective tax rate.  Research and development credits are obtained at a maximum rate of 33.35% of our qualifying research and development expenses, and the increase in the net credit was primarily attributable to an increase in our eligible research and development expenses. Net loss attributable to ordinary shareholders was $32.0 million for the three months ended June 30, 2020, compared to $28.5 million for the same period in 2019. The basic and diluted net loss per ordinary share for the three months ended June 30, 2020 totaled $(0.62) compared to a basic and diluted net loss per ordinary share of $(0.65) for the three months ended June 30, 2019.The Company anticipates that cash on hand is sufficient to fund operations into 2022.Conference Call and Presentation InformationAutolus management will host a conference call today, August 6, at 8:30 a.m. EDT/ 1:30pm BST, to discuss the company’s financial results and operational update.To access the live and subsequent replay, as well as dial in information of this webcast and view the accompanying slide presentation, please register here.About Autolus Therapeutics plcAutolus is a clinical-stage biopharmaceutical company developing next-generation, programmed T cell therapies for the treatment of cancer. Using a broad suite of proprietary and modular T cell programming technologies, the company is engineering precisely targeted, controlled and highly active T cell therapies that are designed to better recognize cancer cells, break down their defense mechanisms and eliminate these cells. Autolus has a pipeline of product candidates in development for the treatment of hematological malignancies and solid tumors. For more information please visit www.autolus.com.Forward-Looking StatementsThis press release contains forward-looking statements within the meaning of the "safe harbor" provisions of the Private Securities Litigation Reform Act of 1995. Forward-looking statements are statements that are not historical facts, and in some cases can be identified by terms such as "may," "will," "could," "expects," "plans," "anticipates," and "believes." These statements include, but are not limited to, statements regarding Autolus’ financial condition and results of operations, including its expected cash runway; the development of Autolus’ product candidates, including statements regarding the timing of initiation, completion and the outcome of preclinical studies or clinical trials and related preparatory work, and the periods during which the results of the studies and trials will become available; Autolus’ plans to research, develop, manufacture and commercialize its product candidates; the potential for Autolus’ product candidates to be alternatives in the therapeutic areas investigated; and Autolus’ manufacturing capabilities and strategy. Any forward-looking statements are based on management's current views and assumptions and involve risks and uncertainties that could cause actual results, performance or events to differ materially from those expressed or implied in such statements. For a discussion of other risks and uncertainties, and other important factors, any of which could cause our actual results to differ from those contained in the forward-looking statements, see the section titled "Risk Factors" in Autolus' Annual Report on Form 20-F filed with the Securities and Exchange Commission on March 3, 2020, as amended, as well as discussions of potential risks, uncertainties, and other important factors in Autolus' future filings with the Securities and Exchange Commission from time to time. All information in this press release is as of the date of the release, and the company undertakes no obligation to publicly update any forward-looking statement, whether as a result of new information, future events, or otherwise, except as required by law.Contact: Lucinda Crabtree, PhD Vice President, Investor Relations and Corporate Communications +44 (0) 7587 372 619 l.crabtree@autolus.comJulia Wilson +44 (0) 7818 430877 j.wilson@autolus.comSusan A. Noonan S.A. Noonan Communications +1-212-966-3650 susan@sanoonan.com Condensed Consolidated Statements of Operations and Comprehensive Loss (Unaudited) (In thousands, except share and per share amounts)       Three Months Ended June 30, Six Months Ended June 30,  2020 2019 2020 2019 Grant income$293   $338   $631   $2,302  Operating expenses:        Research and development(31,328)  (26,173)  (62,615)  (48,738) General and administrative(8,509)  (11,370)  (16,123)  (20,926) Total operating expenses, net(39,544)  (37,205)  (78,107)  (67,362) Other income (expense):        Interest (expense) income(47)  1,073   463   1,615  Other income525   4,380   5,009   3,396  Total other income, net478   5,453   5,472   5,011  Net loss before income tax(39,066)  (31,752)  (72,635)  (62,351) Income tax benefit7,021   3,274   10,717   6,696  Net loss attributable to ordinary shareholders(32,045)  (28,478)  (61,918)  (55,655) Other comprehensive (loss) income:        Foreign currency exchange translation adjustment(1,819)  (8,872)  (19,520)  (3,821) Total comprehensive loss(33,864)  (37,350)  (81,438)  (59,476)          Basic and diluted net loss per ordinary share$(0.62)  $(0.65)  $(1.22)  $(1.34) Weighted-average basic and diluted ordinary shares52,041,340   43,611,531   50,956,566   41,552,718  Condensed Consolidated Balance Sheets (Unaudited) (In thousands, except share and per share amounts)            June 30, 2020 December 31, 2019 Assets    Current assets:    Cash$212,044   $210,643  Restricted cash786   787  Prepaid expenses and other assets, current35,901   37,826  Total current assets248,731   249,256  Non-current assets:    Property and equipment, net30,954   28,164  Right of use assets, net25,100   23,409  Long-term deposits2,354   2,040  Prepaid expenses and other assets, non-current2,813   —  Deferred tax asset410   410  Intangible assets, net186   254  Total assets$310,548   $303,533  Liabilities and shareholders' equity    Current liabilities:    Accounts payable626   1,075  Accrued expenses and other liabilities22,753   21,398  Lease liabilities3,888   2,511  Total current liabilities27,267   24,984  Non-current liabilities:    Lease liabilities24,329   23,710  Total liabilities51,596   48,694       Shareholders' equity:    Ordinary shares, $0.000042 par value; 200,000,000 shares authorized as of June 30, 2020 and December 31, 2019; 52,250,404 and 44,983,006, shares issued and outstanding at June 30, 2020 and December 31, 2019, respectively3   2  Deferred shares, £0.00001 par value; 34,425 shares authorized, issued and outstanding at June 30, 2020 and December 31, 2019—    —   Deferred B shares, £0.00099 par value; 88,893,548 shares authorized, issued and outstanding at June 30, 2020 and December 31, 2019118   118  Deferred C shares, £0.000008 par value; 1 share authorized, issued and outstanding at June 30, 2020 and December 31, 2019—   —  Additional paid-in capital586,110   500,560  Accumulated other comprehensive loss(28,211)  (8,691) Accumulated deficit(299,068)  (237,150) Total shareholders' equity258,952   254,839  Total liabilities and shareholders' equity$310,548   $303,533

  • J.P. Morgan: These 2 Healthcare Stocks Are Must-Watch Names
    TipRanks

    J.P. Morgan: These 2 Healthcare Stocks Are Must-Watch Names

    Marching forward together, the previous decade saw equities and bonds rally right alongside each other. At the same time, there was a negative correlation of daily returns, limiting portfolio volatility. This was a good thing for multi-asset portfolios like pension funds which benefited from the high-low frequency correlation, with declining yields also giving a bump to specific equity market sectors.Today, things have changed, with bond yields landing at almost zero. According to J.P. Morgan strategist Marko Kolanovic, this implies that the trend might be fading away, which poses a major threat to multi-asset portfolios.“Should yields (or inflation expectations) start rising, these portfolios could experience a triple-whammy: bond values would go lower, valuations of the above-described equity market segments would be under pressure, and bond-equity correlation would deteriorate as it is itself correlated with yields,” Kolanovic explained. The strategist added that even if yields don’t rise, in the long run, it’s unlikely that such portfolios will see mid-to-high single-digit returns.So, what does Kolanovic think investors should do? He suggests buying stocks with a more negative correlation to bonds, pointing to value and cyclical names in particular.Offering up concrete recommendations based on Kolanovic’s strategy, the analysts at J.P. Morgan are pounding the table on two stocks, noting that each could climb at least 60% higher in the year ahead. Using TipRanks’ database, we found out that each ticker has also received Buy ratings from the rest of the Street.Autolus Therapeutics (AUTL)Primarily focused on the development of precisely targeted, controlled and highly active T cell therapies, Autolus Therapeutics wants to offer cancer patients treatment options that are superior to the existing standard of care. Given its innovative technology, it’s clear why J.P. Morgan has been impressed by this healthcare name.Writing for the firm, four-star analyst Eric Joseph calls its lead programs, AUTO1 and AUTO3, “potentially best-in-class autologous CAR-T candidate therapies for the treatment of ALL and DLBCL.” When it comes to AUTO1, the available Phase 1/2 data provides a “meaningful de-risking,” with it having the potential to be the first auto-CAR-T therapy approved for both adult and pediatric ALL.Expounding on this, Joseph stated, “Combined, we forecast a worldwide peak sales opportunity of ~$275 million and anticipate U.S. approval for AUTO1 in 2023. Further, as the company is also exploring adoption potential in the outpatient/community oncology setting, we see the safety profile demonstrated to date.”As for AUTO3, its dual CD19/CD22-targeting CAR design makes it a stand-out, in Joseph’s opinion, as it could “yield more durable remissions relative to the currently approved CAR-T class.” In addition, the fact that the asset is more easily tolerated means it could be adopted in an outpatient setting, potentially expanding the addressable DLBCL commercial opportunity. Pivotal development is slated to kick off in 1H21, with regulatory approval potentially coming in 2024. The analyst estimates a worldwide peak sales opportunity of $1.5 billion.To this end, Joseph tells clients to watch out for several possible catalysts in 2H20 including full Phase 1 data for the ALEXANDER study of AUTO3 in DLBCL, long-term follow-up data from the Phase 1 ALLCAR19 study of AUTO1 in adult ALL as well as the initiation of Phase 1 development for AUTO1NG (pediatric ALL), AUTO3NG (DLBCL) and AUTO8 (multiple myeloma).Based on these key catalysts, Joseph commented, “...we believe current AUTL levels undervalue the risk-adjusted commercial potential of these two lead programs in addition to the broader pipeline of CAR-T candidates for heme onc and solid tumor indications.”All of the above convinced Joseph to step over to the bulls’ side. In addition to initiating coverage with an Overweight rating, the analyst set a $25 price target. This target suggests shares could rise 67.5% in the year ahead. (To watch Joseph’s track record, click here) The bulls represent the majority on this one. Out of 8 total reviews published in the last three months, 7 analysts rated the stock a Buy, while only 1 said Hold. So, the word on the Street is that AUTL is a Strong Buy. The $25.29 average price target lands just above Joseph’s and puts the upside potential at 73%. (See AUTL stock analysis on TipRanks)Alexion Pharmaceuticals (ALXN)Targeting rare and devastating diseases, Alexion Pharmaceuticals hopes its therapies will be able to address the unmet medical needs of patients from all over the world. On the heels of its strong Q2 showing, J.P. Morgan thinks that now is the time to pull the trigger.Thanks to continued solid commercial execution across its key franchises, five-star analyst Cory Kasimov tells investors that ALXN was able to deliver double-digit top and bottom-line beats. As a result, management boosted its 2020 guidance for the top and bottom-lines. This is set to be driven by the lower than expected impact to new patient starts in 1H, strong compliance rates across indications, continued conversion to Ultomiris (aHUS in particular) and payer impact that hasn’t been observed yet.Although the new patient queue is slowing and COVID-19 poses a risk to compliance rates, which could have a negative impact on the top-line and operating margins, management announced a commitment to $500-$550 million of repurchases in 2020, increasing to at least one third of free cash flow, on average, from 2021-2023.Looking at its pipeline, it should be noted that ALXN discontinued ALXN-2040 (danicopan) in C3G, much to the dismay of some investors. That being said, plans for the Phase 3 study in PNH are on track.As a reminder, its Soliris therapy got the stamp of approval in 2007 and up until the approval of ALXN’s follow-on product, Ultomiris, in December 2018, it was the only available therapy for the treatment of PNH. Even though Ultomiris wasn’t able to generate superior results over Soliris in Phase 3 studies, its less frequent dosing schedule has enabled the rapid conversion, in Kasimov’s opinion.“We see the rapid conversion of Ultomiris in PNH translating to the aHUS indication, as well continued uptake of Soliris in neurology, which sets up the C5 franchise for a sustainable growth trajectory further supporting the attractive risk/reward profile at the current valuation,” Kasimov said.Based on everything ALXN has going for it, Kasimov reiterated an Overweight rating. He also bumped up the price target from $158 to $167, suggesting 59% upside potential. (To watch Kasimov’s track record, click here) Turning now to the rest of the Street, 10 Buys and 5 Holds have been assigned in the last three months, which add up to a Moderate Buy consensus rating. In addition, the $146.67 average price target brings the upside potential to 41%. (See ALXN stock analysis on TipRanks)To find good ideas for healthcare stocks trading at attractive valuations, visit TipRanks’ Best Stocks to Buy, a newly launched tool that unites all of TipRanks’ equity insights.Disclaimer: The opinions expressed in this article are solely those of the featured analysts. The content is intended to be used for informational purposes only. It is very important to do your own analysis and to consider your own personal circumstances before making any investment.

  • GlobeNewswire

    Autolus announces changes to its Board and Management Team

    Dr. Jay T. Backstrom appointed to board of directorsLONDON, Aug. 04, 2020 (GLOBE NEWSWIRE) -- Autolus Therapeutics plc (Nasdaq: AUTL), a clinical-stage biopharmaceutical company developing next-generation programmed T cell therapies, today announced the appointment of Dr. Jay T Backstrom to its Board of Directors, effective August 1, 2020. Dr. Backstrom currently serves as EVP, Head of Research & Development at Acceleron Pharma Inc (Acceleron) and prior to that served as Chief Medical Officer and Head of Regulatory Affairs at Celgene Corporation. Additionally, the Company announced that Dr. Nushmia Khokhar has been promoted to Senior Vice President, Clinical Development, and will take over the medical leadership role at Autolus.  Dr. Khokhar is a board-certified oncologist with extensive early and late stage clinical development experience, having led several successful registration trials within the industry including the global daratumumab program at Janssen Oncology. Dr. Vijay Peddareddigari, Senior Vice President, Chief Medical Officer, is leaving the Company to return to the US. “We are delighted with Dr. Jay Backstrom’s appointment to the Board of Directors.  Jay brings a wealth of oncology development, regulatory and portfolio strategy experience to the board. Under his leadership Celgene has developed a broad range of therapeutics, including small molecules, biologicals and CAR T programs, in one of the industry’s most significant hemato-oncology pipelines,” said Dr. Christian Itin, chairman and chief executive officer of Autolus. “It is my pleasure to congratulate Dr. Nushmia Khokhar on her appointment as Senior Vice President, Clinical Development and on joining the executive team. Nushmia has been instrumental in overseeing the development of our clinical programs and we look forward to her continued strong leadership. I would also like to thank Vijay for his significant contributions to Autolus and wish him well in his future endeavors. Over the past four years he has played a key leadership role in establishing and executing the clinical development strategy to advance our programmed T cell therapies.”Dr. Backstrom currently serves as EVP, Head of Research & Development at Acceleron, a role that he has held since December 2019. Prior to that, he spent 10 years at Celgene where he latterly served as Chief Medical Officer and Head of Regulatory Affairs with a focus in hematology/oncology. Prior to Celgene, he served as Vice President, Global Medical Affairs and Safety at Pharmion. Dr. Backstrom began his career in industry in 1990 at Marion Merrell Dow and continued as part of its successor companies including Hoechst Marion Roussel, where he held positions in Clinical Research and Global Drug Surveillance and Pharmacoepidemiology. He also spent nearly three years at Quintiles in Medical and Scientific Services, including Therapeutic Head, Cardiovascular, Respiratory and Critical Care, where he oversaw extensive clinical work across a variety of cardiovascular and pulmonary diseases.Prior to his move to industry, Dr. Backstrom served as staff physician and Medical Director of the Samuel U. Rodgers Community Health Center in Kansas City, Missouri. Dr. Backstrom holds an M.D. from Temple University School of Medicine and received post-graduate training in Internal Medicine at Temple University Hospital. He also earned a Master’s in Public Health from Saint Louis University School of Public Health. About Autolus Therapeutics plc Autolus is a clinical-stage biopharmaceutical company developing next-generation, programmed T cell therapies for the treatment of cancer. Using a broad suite of proprietary and modular T cell programming technologies, the company is engineering precisely targeted, controlled and highly active T cell therapies that are designed to better recognize cancer cells, break down their defense mechanisms and eliminate these cells. Autolus has a pipeline of product candidates in development for the treatment of hematological malignancies and solid tumors. For more information please visit www.autolus.com.Contact: Lucinda Crabtree, PhD Vice President, Investor Relations and Corporate Communications +44 (0) 7587 372 619  l.crabtree@autolus.comJulia Wilson +44 (0) 7818 430877 j.wilson@autolus.comSusan A. Noonan S.A. Noonan Communications +1-212-966-3650 susan@sanoonan.com